Presage and Millennium unite to develop cancer drug combos

04/8/2012 | Mass High Tech (Boston)

Presage Biosciences and Millennium: The Takeda Oncology Co. signed a research deal to identify novel cancer drug combinations for treatment of solid tumors. The agreement gives Millennium access to Presage's technology that allows multiple threads of drug candidates to be placed directly into a tumor. Presage will receive an upfront payment and research funding, plus development and regulatory milestone fees.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN